← Browse by Condition
Medical Condition

unresectable nut carcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for unresectable nut carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — unresectable nut carcinoma Clinical Trials

How many clinical trials are currently recruiting for unresectable nut carcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for unresectable nut carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for unresectable nut carcinoma?
unresectable nut carcinoma research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a unresectable nut carcinoma clinical trial?
Eligibility criteria for unresectable nut carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Top Sponsors
National Cancer Institute (NCI) 2 trials
Northwestern University 1 trial

Recruiting Clinical Trials

NCT05372640 Phase 1
Recruiting
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Enrollment
45 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT05019716 Phase 1, Phase 2
Recruiting
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
Enrollment
36 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT07050186 Phase 2
Recruiting
Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma
Enrollment
15 pts
Location
United States
Sponsor
Northwestern University
View Trial →

Related Conditions

metastatic nut carcinoma (3) anatomic stage iii breast cancer ajcc v8 (1) anatomic stage iv breast cancer ajcc v8 (1) metastatic breast carcinoma (1) metastatic malignant solid neoplasm (1) unresectable breast carcinoma (1) unresectable malignant solid neoplasm (1) advanced nut carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology